Global Vagal Nerve Stimulation Market Research Report-Forecast till 2027

$4,450$6,250

The Vagal Nerve Stimulation market is anticipated to surpass USD 1,076.83 million by 2027 with a significant CAGR of 10.30%.

Clear
SKU: MRFR210211 Category: Tag:

Description

Global Vagal Nerve Stimulation (VNS) Market-Forecast till 2027

Vagal Nerve Stimulation Market Overview

The Vagal Nerve Stimulation (VNS) market is anticipated to surpass USD 1,076.83 million by 2027 with a significant CAGR of 10.30% during the forecast period. Vagus nerve stimulation includes the utilization of a gadget to invigorate the vagus nerve with electrical driving forces. An implantable vagus nerve trigger is presently FDA-endorsed to treat epilepsy and melancholy.

The outside Vagal Nerve Stimulation (VNS) gadgets depend totally on electrical signs that can be going through the skin and muscles of the neck without influencing the tissue it is going through. This method should be sufficiently exact to manage and get to explicit action of the nerve.

Development in innovation and the presentation of new outside VNS gadgets are relied upon to fuel the development of the vagal nerve trigger market.

The worldwide Vagal Nerve Stimulation (VNS) market is fundamentally determined by the expanding pervasiveness of neurological problems and rising speculation of biotechnology and drug ventures in R&D.

In any case, factors, for example, the greater expense of the vagal nerve stimulation treatment strategy are relied upon to confine the market’s development during the estimate time frame. Besides, the expanding vital consolidations and acquisitions will set out open doors for market players. However, the higher cost of vagal nerve stimulation treatment procedure is set to hamper the global market growth during the review period.

Segment Overview

The global Vagal Nerve Stimulation (VNS) market has been classified into products, applications, and end-user.
By-Products type the global market is divided into Implantable VNS Devices and External VNS Devices.
Based on Application the market is categorized into depression, epilepsy, and others.
In terms of the end-user segment, the global market is classified into hospitals, ambulatory surgical centers, and others.

Regional Analysis

The global vagal nerve stimulation (VNS) market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.
North America is expected to command the global vagal stimulation (VNS) market with a healthy CAGR of 9.87% during the review period.

the regional market is attributed to the advanced technology, rising prevalence of neurological disorders, increasing healthcare expenditure, and supportive government support for research & development. Europe contributes the second position in the global vagal nerve stimulation market owing to the increasing government support and funding for research & development.

The Asia-Pacific vagal nerve stimulation market is expected to register a significant CAGR of 10.69% during the study period. The regional market is attributed to the existence of rapidly developing healthcare technology, a large patient population, and increased healthcare expenditure. The Rest of the World’s vagal nerve stimulation market is categorized into two major regions, namely the Middle East & Africa and Latin America.

Key Competitors

The major players of the global vagal nerve stimulation market are LivaNova, PLC (UK), ReShape Lifesciences Inc (US), ElectroCore Medical LLC (US), Boston Scientific Corporation (US), NeuroMetrix, Inc. (US), ImThera Medical, Inc. (US), Inspire Medical Systems, Inc (US), Parasym Ltd (UK), and Innovative Health Solutions, Inc. (the US).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.

Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Global Nerve Repair and Regeneration Market: Market Segments: By Product (Neurostimulation and Neuromodulation Devices, Biomaterials); By Application (Neurostimulation and Neuromodulation Surgeries, Diagnostics, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy); By End User (Hospitals, Ambulatory Surgical Centers and Clinics); and Region – Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 MARKET ATTRACTIVENESS ANALYSIS

1.1.1 GLOBAL VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2019

1.1.2 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION, 2019

1.1.3 GLOBAL VAGAL NERVE STIMULATION MARKET, BY END USER

1.1.4 GLOBAL VAGAL NERVE STIMULATION MARKET, BY REGION

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 RESEARCH PROCESS

3.2 PRIMARY RESEARCH

3.3 SECONDARY RESEARCH

3.4 MARKET SIZE ESTIMATION

3.5 TOP DOWN & BOTTOM-UP APPROACH

3.6 FORECAST MODEL

3.7 LIST OF ASSUMPTIONS& LIMITATIONS

4 MARKET DYNAMICS

4.1 INTRODUCTION

4.2 DRIVERS

4.2.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS

4.2.2 INCREASING INVESTMENT OF BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES IN R&D

4.2.3 DRIVERS IMPACT ANALYSIS

4.3 RESTRAINTS

4.3.1 HIGHER COST OF VAGAL NERVE STIMULATIO TREATMENT PROCEDURE

4.3.2 RESTRAINTS IMPACT ANALYSIS

4.4 OPPORTUNITIES

4.4.1 INCREASING STRATEGIC MERGERS AND ACQUISITIONS

4.5 IMPACT OF COVID-19 ON THE GLOBAL VAGAL NERVE STIMULATION MARKET

4.5.1 IMPACT ON SUPPLY CHAIN

4.5.2 IMPACT ON PRODUCTION

4.5.3 IMPACT ON PRICING

5 MARKET FACTOR ANALYSIS

5.1 SUPPLY/VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 BARGAINING POWER OF BUYERS

5.2.4 THREAT OF SUBSTITUTES

5.2.5 INTENSITY OF RIVALRY

5.3 GLOBAL VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME

5.4 EUROPE VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME

5.5 US VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME

5.6 VNS DEVICE IMPLEMENTED PATIENTS, BY COUNTRY, 2019

6 GLOBAL VAGAL NERVE STIMULATION MARKET, BY PRODUCTS

6.1 OVERVIEW

6.2 IMPLANTABLE VNS DEVICES

6.3 EXTERNAL VNS DEVICES

7 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION

7.1 OVERVIEW

7.2 DEPRESSION

7.3 EPILEPSY

7.4 OTHERS

8 GLOBAL VAGAL NERVE STIMULATION MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS

8.3 AMBULATORY SURGICAL CENTERS

8.4 OTHERS

9 GLOBAL VAGAL NERVE STIMULATION MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA.

9.3 EUROPE

9.3.1 GERMANY

9.3.2 FRANCE.

9.3.3 UK

9.3.4 ITALY

9.3.5 SPAIN.

9.3.6 REST OF EUROPE.

9.4 ASIA-PACIFIC

9.4.1 CHINA

9.4.2 INDIA.

9.4.3 JAPAN.

9.4.4 AUSTRALIA.

9.4.5 SOUTH KOREA.

9.4.6 REST OF ASIA-PACIFIC.

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST

9.5.2 AFRICA.

9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 COMPETITIVE OVERVIEW

10.2 GLOBAL VAGAL NERVE STIMULATION MARKET: COMPANY SHARE ANALYSIS

10.3 COMPETITIVE BENCHMARKING

10.4 MAJOR GROWTH STRATEGY IN THE GLOBAL VAGAL NERVE STIMULATION MARKET

10.5 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL VAGAL NERVE STIMULATION MARKET

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 NEW PRODUCTS LAUNCH/SERVICE DEPLOYMENT

10.6.2 MERGER & ACQUISITION

10.6.3 COLLABORATION

10.7 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO

10.7.1 SALES & OPERATING INCOME

10.7.2 R&D EXPENDITURE

11 COMPANY PROFILES

11.1 LIVANOVA PLC

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 RESHAPE LIFESCIENCES, INC.

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 ELECTROCORE MEDICAL LLC

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGIES

11.4 BOSTON SCIENTIFIC CORPORATION

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 NEUROMETRIX, INC.

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 SWOT ANALYSIS

11.5.6 KEY STRATEGIES

11.6 IMTHERA MEDICAL INC.

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 SWOT ANALYSIS

11.6.5 KEY STRATEGIES

11.7 INSPIRE MEDICAL SYSTEMS, INC.

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 SWOT ANALYSIS

11.7.6 KEY STRATEGIES

11.8 PARASYM LTD

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 SWOT ANALYSIS

11.8.6 KEY STRATEGIES

11.9 INNOVATIVE HEALTH SOLUTIONS INC.

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 PRODUCTS OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 SWOT ANALYSIS

11.9.6 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS